Dan Lyne

Executive Vice President

Photo of dan-lyne

Professional Experience

Find Your Perfect Space


Search Properties

Associated Office

Location

300 N LaSalle
Suite 600
Chicago, IL 60654

Get Directions

Dan Lyne is an Executive Vice President on the Advisory & Transaction Services team for CBRE. He holds leadership positions for both the Global Health & Life Sciences Practice, as well as the Global Technology & Media Practice. Dan’s career has long focused on the interdependence of life science disciplines with advanced technologies and data analytics.

A well-regarded leader throughout the Chicago business community, Dan represents clients both large and small on complex real estate transactions. Dan is also a senior advisor on public/private client engagements and manages portfolio company services for several notable venture capital and private equity funds. Through his career, he has advised and led transactions for a wide range of both tenants and investors/developers including: 

  • Novartis Gene Therapies
  • Xeris Pharmaceuticals
  • AveXis
  • Baird Venture Capital 
  • Portal Innovations 
  • Builder’s Vision & S2G Ventures
  • The American Medical Association
  • Motorola Solutions
  • Lightbank
  • Horizon Therapeutics
  • Soli Organics
  • P33
  • PayPal
  • Whirlpool
  • SMS-Assist
  • Assertio
  • Spotify USA
  • DocuSign
  • The State of Illinois
  • The University of Chicago
  • Trammell Crow Company
  • Ventas
  • Wexford Life Sciences
  • Beacon Capital Partners
  • Aptinyx

As it is his passion, Dan has focused much of his career on addressing talent attraction and corporate culture via the need for transformational and world-class creative space and R&D environments.

Dan is also the co-founder of "1871" – a 170,000 square foot co-working center for digital startups located in Chicago’s famed Merchandise Mart. Two years later, Dan was on the
founding team that launched MATTER, a 25,000 square foot co-working venture dedicated to entrepreneurs focused on healthcare and life sciences innovation.